HAO Capital: one of the top 50 foreign PE companies in China

Screen Shot 2015-01-23 at 3.04.13 pm

HAO Capital has been recognized as a top 50 foreign private equity company in China in 2014. This is the third consecutive year HAO has won this accolade at the China Venture Capital & Private Equity Awards.

The awards are organized by Zero2IPO, a leading Chinese PE/VC industry information provider. They evaluate thousands of active PE/VC players in China on their performance with respect to fund raising, investment, portfolio management and exit activities.

For more information, please click here.

HAO Capital remains a top 50 PE Investor in China in 2013

HAO Capital was recognized as a top 50 Private Equity Investor in China in 2013, the second year in a row it has achieved this honour.

The awards are organized by Zero2IPO, a leading Chinese PE/VC industry information provider, evaluating thousands of active PE/VC players in China on their performance with respect to fund raising, investment, portfolio management and exit activities.

For more information click here

Rising Star: Wong Races to Third Fund After Carlyle Apprenticeship

“At a young age, she is already an old hand, and a good one at that,” U.S. venture capital veteran Robert Grady told Private Equity Analyst when describing his former Carlyle Group protégé Elaine Wong, now a founder and partner at HAO Capital in China.

Indeed, at only 36, Ms. Wong’s Beijing-based firm is already gearing up for a third fund that could total around $500 million, while she sits on the boards of Chinese companies, including home furnishings company Ju Tai Long.

Originally a scientist, with a chemical engineering degree from the Massachusetts Institute of Technology, Ms. Wong decided to embark on a career in investment after realizing laboratory work wasn’t her forte, encouraged by a friend who worked at Carlyle.

In 1999, she accepted a job at Carlyle in the U.S., admitting that at that time she knew little about the industry. She found her feet quickly: One early deal saw her involved in multiple investments in Blackboard Inc., a developer of e-learning software for universities, for Carlyle Venture Partners. In 2011, Blackboard, which had since listed on Nasdaq, was bought out by Providence Equity Partners for $1.64 billion. “Elaine had the background and intellectual capacity to understand the technology,” said Mr. Grady.

In 2001, Ms. Wong decided to pursue an M.B.A from Stanford University that would help hone her “softer” skills, she said. One particular class that has proved useful to this day, she explained, was interpersonal dynamics, also known as “touchy feely,” which has come in useful when working with entrepreneurs.

On graduating, she returned to Carlyle, but this time for its Asia operations. “The early 2000s were a good time for Western VCs in China – the government was welcoming of the know-how, the investing expertise and the technology domain knowledge being used to assist China’s growth,” said Mr. Grady. It did, however, take more leg work when it came to deal sourcing as the market was immature, said Ms. Wong.

After several years with Carlyle, which saw the firm invest in Chinese companies such as C-Trip, an online travel agency that now trades publicly, Ms. Wong decided to set up on her own firm, founding HAO Capital in 2006.

She said that persuading some limited partners to back a China-only fund was a challenge, as many preferred to hedge their investments via a pan-Asian vehicle. In 2006, “people were intrigued by China, but not everyone was ready to pull that trigger” and invest in a solely China-focused vehicle, said Ms. Wong. Fast forward six years, and the firm now manages around $500 million across two funds, according to HAO Capital’s website. Ms. Wong said the firm targets a five-times return on its investments.

HAO invests in consumer, health care and light industrial companies, typically targeting a 10% to 25% shareholding, with deal size ranging from 80 million yuan ($13 million) to 300 million yuan. It has established alliances with other China-based businesses such as home-grown private equity firm Harlyn Capital. In July of last year, Hao teamed up with Guangdong-based consumer electronics company TCL Corp. to form a joint venture that will invest in Chinese diagnostic imaging companies.

HAO’s portfolio includes LP Amina, which provides environmental and energy technology services for electric utility plants, and mobile payment platform company HiSunPay. It has seen exits from the likes of China Cord Blood Corp, a health-care company that listed on the New York Stock Exchange in 2009, and waste management business ZhongDe Waste Technology AG, which went public on the Frankfurt exchange in 2007.

Dow Jones

Asian Firms Look Beyond Stock Sales to Raise Funds

Simon Eckersley, CEO and Co-founder of HAO Capital, talks to CNBC about seeing Chinese companies increasingly turning to private equity for capital when IPO markets are sluggish.

A drought in the IPO market has more Asian firms looking into alternative ways to raise capital, with many tapping private equity and debt markets.

Global investment firm Piper Jaffray says there’s been a 25 percent increase in demand for both private equity and bank loans from regional clients in past two months, as turmoil ripped through global stock markets.

“Some companies that do need the capital… are clearly trying to get more comfortable with gearing some more bank debt; and, when necessary, if they still need more capital, they will turn towards the private equity and venture capital community,” said Hong Kong-based J. West Riggs, who is Managing Director and Head of Asia Equity Capital Markets at the firm.

Asia’s struggling IPO market has resulted in only 25 listings in the first six months of this year on the main board of the Hong Kong Stock Exchange, compared to 42 deals for the same period in 2011. Only six of this year’s listings were greater than $100 million, pointing shaky investor interest in what has been considered the world’s biggest market for IPOs in two of the past three years.

As a result, China-focused private equity firm HAO Capital is seeing more companies that haven’t been able to raise funds in the stock market this year.

“We are coming across more companies that have tried to go public and raise capital in the public markets and haven’t been successful like a delayed IPO or they filed in the U.S. and it didn’t happen and now they are looking at a private round of financing,” said CEO and Co-Founder Simon Eckersley.

While there are more opportunities for private equity investors, Eckersley notes that the current market conditions have made it difficult to exit from the investments.

For Singapore-based UOB Venture Management, the investment horizon for their private equity funds is now longer as listings get delayed.

“Investee companies need funding for a longer period of time, before they eventually do an IPO,” the firm said.

“Overseas exits are particularly difficult at the moment,” Eckersley said. “I think the China market is still open for business, but IPOs outside China are more difficult at the moment.”

Chang Tou Chen, Managing Director and Head of Global Banking of South East Asia at HSBC, adds that while private equity firms are becoming more relevant in Asia, the control factor over companies still limits their reach in the region.

“Many companies in Asia are either state owned or family owned, and families don’t like to lose control of companies to private equity,” Chang said.

“If it [IPOs] doesn’t pick up then the private equity alternative will continue to increase in demand and then the other alternative will be mergers and acquisitions,” Riggs said. “So there will be some companies that may be forced to look for strategic buyers.”

HAO Capital: Helping Chinese Companies Grow

Since its establishment in 2005, HAO Capital has been focusing on consumer, healthcare and industrial investments, such as SKR, China Cord Blood, Buchang Pharma, Ju Tai Long and LP Amina. In an exclusive interview with PE Daily, Elaine Wong, Partner and Co-founder of HAO Capital talked about HAO Capital’s vision to help Chinese companies grow, its unique investment thesis and how to become the trusted partner of entrepreneurs.

Though trying to stay a low profile in the past, HAO Capital is quite a well-recognized brand in the investment world and a trusted partner to entrepreneurs. Since its establishment in 2005, HAO Capital has been focusing on consumer, healthcare and industrial, with representative investments in SKR, China Cord Blood, Buchang Pharma, Ju Tai Long and LP Amina. In the recent exclusive interview with PE Daily, Elaine Wong, Partner and Co-founder of HAO Capital talked about HAO Capital’s vision to help Chinese companies grow and its unique investment thesis and story to become trusted partner of the entrepreneurs.

View the whole news in Chinese

Pressure in Private Equity

Elaine Wong, Founder and Partner of HAO Capital, was quoted in the Wall Street Journal story on the limitations of IPO exits for PE/VC in China. “Statistically speaking, given the limited number of companies that can go public each year, there are more companies backed by private equity and venture capital than there are IPO opportunities.”

Three of China’s biggest private-equity funds have agreed to buy control of a company from another fund, a rare move that underscores a mismatch between deal money and potential targets in the world’s largest growth market, as well as limited ways for funds to exit investments.

CDH Capital, Citic Private Equity and New Horizon Capital have agreed to buy MBK Partners’ more than 50% stake in the parent company of Singapore-listed LuyePharma Group Ltd., said a person familiar with the deal. The parent firm, Luye Pharmaceutical Investment Co., holds 77% of LuyePharma.

Details were unavailable, but the person said the stake sold at a premium to its market value. Shares of LuyePharma closed Thursday at 94 Singapore cents (75 U.S. cents), valuing the 50% stake at US$140 million.

An influx of new money seeking opportunities in China’s heady growth market is heightening competition for deals, spurring cash-flush funds to look for different opportunities. According to data from Zero2IPO Research, a Beijing-based firm that tracks China’s private-equity industry, private-equity and venture-capital funds in China raised almost $67.1 billion last year, 73% more than the $38.8 billion raised in 2010. Only $18.9 billion was raised in 2009. In 2011, funds invested $40.6 billion in deals in China, up from $15.8 billion in 2010.

“There are tons of funds that are struggling to deploy their funds wisely,” said Ludvig Nilsson, managing director of Jade Invest, an advisory firm focused on private equity.

Private-equity and venture-capital funds invested in 2,200 deals last year, almost double the 1,180 struck in 2010, according to Zero2IPO. There were only 594 in 2009.

What makes the LuyePharma deal unusual in China is the transfer of a stake from private equity to private equity, and underscores the difficulty of exiting deals. Private-equity funds in China typically prefer to go through initial public offerings. Such deals have been lucrative, with TPG’s investment in Shenzhen Development Bank Co. and Carlyle Group LP’s stake in China Pacific Insurance (Group) Co. notably earning big returns.

But the IPO market could become clogged with private-equity-backed companies. The first wave of funds to set up in China is nearing the end of its cycle, and the funds need to return capital to their investors.

Unlike in the U.S., where companies can publicly list shares if they fulfill criteria set by the exchanges, in China the securities regulator decides who can launch an IPO and when, resulting in long waits.

Last year, 171 Chinese companies backed by private equity and venture capital issued IPOs globally, compared with 221 in 2010, according to Zero2IPO.

“Statistically speaking, given the limited number of companies that can go public each year, there are more companies backed by private equity and venture capital than there are IPO opportunities,” said Elaine Wong, founder and partner of HAO Capital, a China-focused private-equity firm.

That will result in more funds either looking to sell to another private-equity fund or to a company. “We’re seeing [funds] who want to sell an asset because they haven’t been able to exit how they envisioned,” said Mr. Nilsson. “There will be more of these in the next two years.”

HAO Capital: We Have Faith in China

In an interview with China Economic Times, Simon Eckersley, Founder and CEO of HAO Capital, a China focused Private Equity firm, said he remained confident in investment opportunities in China. “Despite a sluggish economic recovery worldwide, we have faith in China. We are investors who partner with entrepreneurs to build their companies into leaders in their markets.”

China Economic Times: Tell me something about HAO Capital.

Simon Eckersley: HAO Capital is a China focused Private Equity firm based in Beijing and Hong Kong, providing growth capital to Chinese companies. Founded in 2005 by three seasoned investment professionals, we currently manage total assets of USD 500mn across two funds.

We are biased for investments in Consumer, Healthcare and Light Industrial, including Clean/Greentech. Our targeting investments vary from RMB 80mn to RMB 300mn with target ownership ranging from 10-25%.

Our LP’s include institutional investors and high net worth individuals.

China Economic Times: What are HAO Capital’s target industries?

Simon Eckersley: We have invested in nearly 20 companies, five of which had already listed overseas. Our portfolio includes Ju Tai Long – a leading furniture retailer, Buchang Pharma, SKR – a medical devices and services platform, LP Amina – an environmental service company for the power industry, etc.

China Economic Times: From your perspective, which industries will become HAO Capital’s investment target in the future?

Simon Eckersley: HAO Capital will be more focused on Consumer, Healthcare, Greentech, energy saving and environmental protection industry in the future.

China Economic Times: Why do you attach great importance to these segmented markets?

Simon Eckersley: We clearly see some economic and social driving forces emerging in China, such as growth of domestic consumption, enhancement of consumers’ brand awareness, the growth in demand for products’ quality and safety, increasing demand from lower tier cities, requirement for sustainable development, aging population and improvement in social welfare and security, etc.

China Economic Times: Does HAO Capital have any specific investment plans in the Chinese market in the near future?

Simon Eckersley: Despite sluggish economy recovery worldwide, we have faith in China.  We are investors who partner with entrepreneurs to build their companies into leaders in their markets. We work with entrepreneurs who have a passion for addressing the challenges of growing their company and taking advantage of growth opportunities. Our focus is on companies that have an interest in creating competitive advantage through superior products, services, technology, management and/or access to unique resources.

Credit Crunch

Wenzhou, the manufacturing center of China, faces shutdowns as private moneylenders demand loans be repaid before Chinese New Year. Simon Eckersley, founder and CEO of HAO Capital, a private equity firm with offices in Beijing and Hong Kong, says, however, it is wrong to see Wenzhou’s problems as being unique.

He cites the problems that Western SMEs currently have in getting loans from European and American banks still trying to restore their balance sheets in the aftermath of the economic crisis.

“I don’t think it is a reflection of a broader problem of the Chinese economy because you also have it in Japan and in the UK,” he says.

He says if businesses cannot demonstrate their competitiveness in any market at present, they are going to find it difficult to get money.

“This is the case in every country and every region. China’s growth is maintaining its momentum, and the credit crisis in one region cannot reflect the whole picture.”

View the whole news on China Daily